CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 4 Derivatives Options or other derivatives
- 144 Insider Sale of Securities
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Planned sale CHIEF OPERATING OFFICER sold 4,875 shares at $15.11 ($73,658)
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale 10% owner sold 500,000 shares at $15.00 ($7,500,000)
- SC 13D/A Stake Beneficial Ownership Report
- 4 Planned sale Director sold 1,270 shares at $16.41 ($20,840)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,000 shares at $15.85 ($190,256)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at $15.81 ($51,388)
- 4 Planned sale President and CEO sold 12,000 shares at an average $15.69 ($188,229)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Operating Officer sold 4,875 shares at $15.14 ($73,783)
- 4 Planned sale Chief Scientific Officer sold 12,000 shares at an average $14.28 ($171,381)
- 4 Planned sale Chief Operating Officer sold 13,540 shares at an average $15.02 ($203,348)
Page 24 of 40 · 798 filings